Exchange: NASDAQ·Updated 06:46 PM EST

ENVB News

News
all
press releases
Enveric Biosciences Reports Financial Results for Third Quarter 2026 and Provides Corporate Update
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2026, and provided a...
Business Wire
Enveric Biosciences Reports Financial Results for Third Quarter 2026 and Provides Corporate Update
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2026, and provided a...
Business Wire
More News
Enveric Biosciences reports positive preclinical qEEG results for EB-003, confirming brain activity and favorable safety in mice.read more...
Benzinga
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced results from a quantitative electroencephalography (qEEG) study of its lead candidate...
Business Wire
Enveric Biosciences posts positive preclinical data for EB-003, showing favorable absorption and safety for psychiatric therapies.read more...
Benzinga
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced positive results from recently completed IND-enabling in vitro Absorption...
Business Wire
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark...
Business Wire
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that Joseph Tucker, Ph.D., CEO of Enveric will deliver a virtual presentation at the...
Business Wire
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2026, and provided a...
Business Wire
Enveric Biosciences reports new preclinical data supporting the non-hallucinogenic profile of its lead psychiatric drug candidate, EB-003.read more...
Benzinga
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced new preclinical data that further supports the growing body of evidence reinforcing...
Business Wire

Advertisement|Remove ads.